Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRROR study of cetuximab-IRDye800CW plus 5-ALA for fluorescence-guided surgery in high-grade glioma
NL-OMON53583Phase 1Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW, cetuximab, 5-aminolevulinic acid and clemastine in glioma, sponsored by University Medical Center Groningen. Primary endpoints: Safety of cetuximab-IRDye800CW, Feasibility of fluorescence-guided surgery with cetuximab-IRDye800CW and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
cetuximab-IRDye 800CWcetuximab5-aminolevulinic acidclemastine
03
Conditions
glioma
Beyond the preview
Go deeper on NL-OMON53583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53583.